Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy. (Q54782071)

From Wikidata

Jump to navigation Jump to search

scientific article

edit

Language	Label	Description	Also known as
English	Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy.	scientific article

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18980548

retrieved

3 June 2018

reference URL

http://europepmc.org/abstract/MED/18980548

title

Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy. (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18980548

retrieved

3 June 2018

reference URL

http://europepmc.org/abstract/MED/18980548

main subject

endothelium

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

chemotherapy

1 reference

based on heuristic

inferred from title

antibody

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

systemic therapy

1 reference

based on heuristic

inferred from title

author

National Comprehensive Cancer Network

series ordinal

2

object named as

National Comprehensive Cancer Network

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18980548

retrieved

3 June 2018

author name string

Paul F Engstrom

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18980548

retrieved

3 June 2018

reference URL

http://europepmc.org/abstract/MED/18980548

language of work or name

English

0 references

publication date

1 November 2008

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18980548

retrieved

3 June 2018

reference URL

http://europepmc.org/abstract/MED/18980548

published in

Pharmacotherapy

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18980548

retrieved

3 June 2018

reference URL

http://europepmc.org/abstract/MED/18980548

volume

28

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18980548

retrieved

3 June 2018

reference URL

http://europepmc.org/abstract/MED/18980548

issue

11 Pt 2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18980548

retrieved

3 June 2018

reference URL

http://europepmc.org/abstract/MED/18980548

page(s)

18S-22S

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18980548

retrieved

3 June 2018

reference URL

http://europepmc.org/abstract/MED/18980548

cites work

Cancer statistics, 2008

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.18S

retrieved

21 January 2018

A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.18S

retrieved

21 January 2018

The continuum of care: a paradigm for the management of metastatic colorectal cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.18S

retrieved

21 January 2018

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.18S

retrieved

21 January 2018

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.18S

retrieved

21 January 2018

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.18S

retrieved

21 January 2018

Identifiers

DOI

10.1592/PHCO.28.11-SUPP.18S

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18980548

retrieved

3 June 2018

reference URL

http://europepmc.org/abstract/MED/18980548

PubMed publication ID

18980548

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18980548

retrieved

3 June 2018

reference URL

http://europepmc.org/abstract/MED/18980548

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54782071&oldid=1502331332"